A Study of the Safety and Efficacy of a New Treatment for Non-Infectious Intermediate or Posterior Uveitis
Primary Purpose
Intermediate Uveitis, Posterior Uveitis
Status
Completed
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
Dexamethasone
dexamethasone
Sham injection
Sponsored by

About this trial
This is an interventional treatment trial for Intermediate Uveitis
Eligibility Criteria
Inclusion Criteria: 18 years or older with a diagnosis of chronic intermediate uveitis in at least one eye Exclusion Criteria: Uncontrolled systemic disease Any active ocular infections
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Active Comparator
Active Comparator
Sham Comparator
Arm Label
1
2
3
Arm Description
Dexamethasone 350 µg
Dexamethasone 700 µg
Sham
Outcomes
Primary Outcome Measures
Percentage of Patients With Vitreous Haze (Ocular Inflammation) Score of Zero
Percentage of patients with Vitreous Haze Score of Zero at Week 8. Score is based on standardized scale of 0 to +4 where 0 equals no inflammation and +4 equals optic nerve head not visible (severe).
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT00333814
Brief Title
A Study of the Safety and Efficacy of a New Treatment for Non-Infectious Intermediate or Posterior Uveitis
Study Type
Interventional
2. Study Status
Record Verification Date
March 2011
Overall Recruitment Status
Completed
Study Start Date
May 2006 (undefined)
Primary Completion Date
December 2008 (Actual)
Study Completion Date
April 2009 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
Allergan
4. Oversight
5. Study Description
Brief Summary
This study will evaluate the safety and efficacy of an intravitreal implant of dexamethasone for the treatment of non-infectious intermediate or posterior uveitis.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Intermediate Uveitis, Posterior Uveitis
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2, Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
229 (Actual)
8. Arms, Groups, and Interventions
Arm Title
1
Arm Type
Active Comparator
Arm Description
Dexamethasone 350 µg
Arm Title
2
Arm Type
Active Comparator
Arm Description
Dexamethasone 700 µg
Arm Title
3
Arm Type
Sham Comparator
Arm Description
Sham
Intervention Type
Drug
Intervention Name(s)
Dexamethasone
Other Intervention Name(s)
Posurdex®
Intervention Description
Dexamethasone 350 µg; injection drug delivery system at Day 0
Intervention Type
Drug
Intervention Name(s)
dexamethasone
Other Intervention Name(s)
Posurdex®
Intervention Description
Dexamethasone 700 µg injection drug delivery system at Day 0
Intervention Type
Drug
Intervention Name(s)
Sham injection
Intervention Description
Sham injection at Day 0
Primary Outcome Measure Information:
Title
Percentage of Patients With Vitreous Haze (Ocular Inflammation) Score of Zero
Description
Percentage of patients with Vitreous Haze Score of Zero at Week 8. Score is based on standardized scale of 0 to +4 where 0 equals no inflammation and +4 equals optic nerve head not visible (severe).
Time Frame
Week 8
Other Pre-specified Outcome Measures:
Title
Percentage of Patients With at Least a 15-Letter Improvement in Best Corrected Visual Acuity (BCVA)
Description
Percentage of Patients with at least a 15-letter improvement in BCVA at Week 8 from Baseline. BCVA is measured using an eye chart and is reported as the number of letters read correctly (ranging from 0 to 100 letters). The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). The higher the number of letters read correctly, the better the vision (or visual acuity). An improvement in the number of letters read means that the vision has improved.
Time Frame
Week 8
Title
Percentage of Patients With at Least a 10-Point Improvement in the National Eye Institute Visual Functioning Questionnaire-25 (NEI-VFQ-25)Score
Description
Percentage of patients with at least a 10-Point Improvement in the NEI-VFQ-25 over-all composite score at Week 8 from Baseline. The NEI-VFQ-25 consists of 25 vision-targeted questions plus one general health question resulting in a score of 0-100 (100 represents best functionality).
Time Frame
Week 8
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
18 years or older with a diagnosis of chronic intermediate uveitis in at least one eye
Exclusion Criteria:
Uncontrolled systemic disease
Any active ocular infections
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Medical Director
Organizational Affiliation
Allergan
Official's Role
Study Director
Facility Information:
City
Dallas
State/Province
Texas
Country
United States
City
Sydney
Country
Australia
City
Vienna
Country
Austria
City
São Paulo
State/Province
São Paulo/SP
Country
Brazil
City
Montreal
State/Province
Quebec
Country
Canada
City
Prague
Country
Czech Republic
City
Paris
Country
France
City
Heidelberg
Country
Germany
City
Holargos
Country
Greece
City
Hyderabad
Country
India
City
Petah Tikva
Country
Israel
City
Seoul
Country
Korea, Republic of
City
Gdansk
Country
Poland
City
Coimbra
Country
Portugal
City
Johannesburg
Country
South Africa
City
Madrid
Country
Spain
City
Lausanne
Country
Switzerland
City
London
Country
United Kingdom
12. IPD Sharing Statement
Citations:
PubMed Identifier
23761087
Citation
Lightman S, Belfort R Jr, Naik RK, Lowder C, Foster CS, Rentz AM, Cui H, Whitcup SM, Kowalski JW, Revicki DA. Vision-related functioning outcomes of dexamethasone intravitreal implant in noninfectious intermediate or posterior uveitis. Invest Ophthalmol Vis Sci. 2013 Jul 18;54(7):4864-70. doi: 10.1167/iovs.12-10981.
Results Reference
derived
PubMed Identifier
23411886
Citation
Naik RK, Rentz AM, Foster CS, Lightman S, Belfort R Jr, Lowder C, Whitcup SM, Kowalski JW, Revicki DA. Normative comparison of patient-reported outcomes in patients with noninfectious uveitis. JAMA Ophthalmol. 2013 Feb;131(2):219-25. doi: 10.1001/2013.jamaophthalmol.102.
Results Reference
derived
PubMed Identifier
21220619
Citation
Lowder C, Belfort R Jr, Lightman S, Foster CS, Robinson MR, Schiffman RM, Li XY, Cui H, Whitcup SM; Ozurdex HURON Study Group. Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol. 2011 May;129(5):545-53. doi: 10.1001/archophthalmol.2010.339. Epub 2011 Jan 10.
Results Reference
derived
Links:
URL
http://www.allerganclinicaltrials.com/inquiries/trialsubject.aspx
Description
Related Info
Learn more about this trial
A Study of the Safety and Efficacy of a New Treatment for Non-Infectious Intermediate or Posterior Uveitis
We'll reach out to this number within 24 hrs